Several studies have indicated that T-DM1 can also exhibit favorable therapeutic effects in patients with HER2-mutant non-small cell lung cancer (53); SG has been beneficial for patients with breast cancer with brain metastases and recurrent glioblastoma (54); These findings are similar to our conclusions. Here, ERBB2 is linked to non-small cell lung carcinoma.